慢性骨髓性白血病治療的全球市場:各藥物類型(蛋白酪氨酸激酶抑制劑，代謝拮抗劑，其他)，各流通管道，各地區-規模，佔有率，展望，機會分析(2021年～2028年)

主要企業的藥物的上市數增加，預計促進在預測期間內的市場成長。還有主要企業的策略性聯盟等的無機性成長策略增加，預計也促進市場成長。

本報告提供全球慢性骨髓性白血病治療市場的相關調查，市場展望，市場動態，市場分析，競爭情形等全面性資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

• 報告的說明
  • 市場定義和範圍
• 摘要整理
  • 市場明細:各藥物類型
  • 市場明細:各流通管道
  • 市場明細:各地區
• Coherent Opportunity Map(COM)

第3章 市場動態，法規，及趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 影響分析
• 重要的開發
• PEST分析
• 法規情境
• 開發平台分析
• 新產品的銷售/核准
• 流行病學
• 市場趨勢

第4章 COVID-19影響分析

• 經濟影響
• COVID-19流行病學
• 對應COVID-19的政府舉措

第5章 全球慢性骨髓性白血病治療市場:各藥物類型(100萬美元)(2017年～2028年)

• 簡介
• 蛋白酪氨酸激酶抑制劑
• 代謝拮抗劑
• 其他

第6章 全球慢性骨髓性白血病治療市場:各流通管道(100萬美元)(2017年～2028年)

• 簡介
• 醫院藥局
• 零售藥局
• 線上藥局

第7章 全球慢性骨髓性白血病治療市場:各地區(100萬美元)(2017年～2028年)

• 簡介
• 北美
• 南美
• 歐洲
• 亞太地區
• 中東
• 非洲

第8章 競爭情形

• 企業簡介
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited
  • Innovent Biologics, Inc.
  • Viatris Inc.(Mylan NV)
  • Lupin
  • IL-YANG PHARM CO. LTD.
  • Million Health Pharmaceuticals
  • Celon Labs
• 分析師的見解

第9章 Section

Chronic myeloid leukemia (CML) is a cancer that initiates in the blood-forming cells of the bone marrow and enters the blood. It increases the number of white blood cells in the blood. Chronic myeloid leukemia is also known as chronic myelogenous leukemia. Chronic myeloid leukemia (CML) occurs mostly in adults, and rarely in children. Chronic myeloid leukemia (CML) is detected after the blood test is performed.

Chronic myeloid leukemia symptoms includes:

• Bone pain
• Easy bleeding
• Fever
• Weight loss
• Excessive sweating during sleep

Market Dynamics

Increasing number of drug launches by market key players is expected to drive the growth of global chronic myeloid leukemia treatment market during the forecast period. For instance, in September 2017, Mylan N.V., a pharmaceutical company, announced the launch of Imatinib Mesylate tablets, 100 mg and 400 mg, a generic version of Novartis's Gleevec Tablets. Moreover, Mesylate tablets are approved by US Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic eosinophilic leukemia or hypereosinophilic syndrome, chronic myelogenous leukemia, and others.

Increasing number of inorganic growth strategies such as strategic collaboration by market key players is expected to drive the growth of global chronic myeloid leukemia treatment market. For instance, in July 2021, Innovent Biologics, Inc., a biopharmaceutical company, announced strategic collaboration with Ascentage Pharma, a biopharmaceutical company. Moreover, this collaboration includes the joint clinical development and commercialization of HQP1351 (olverembatinib), a third-generation BCR-ABL inhibitor in China. Olverembatinib is indicated for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP).

Key features of the study:

• This report provides an in-depth analysis of global chronic myeloid leukemia treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players

• It profiles leading players in the global chronic myeloid leukemia treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.

• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc. (Mylan N.V.), Lupin, IL-YANG PHARM CO. LTD., Million Health Pharmaceuticals, and Celon Labs

• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

• The global chronic myeloid leukemia treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.

• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global chronic myeloid leukemia treatment market

Detailed Segmentation:

• Global Chronic Myeloid Leukemia Treatment Market, By Drug Type:
• Tyrosine Kinase Inhibitors
  • Imatinib (Gleevac)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Bosutinib (Bosulif)
  • Ponatinib (Iclusig)
  • Asciminib (Scemblix)
  • Others
• Antimetabolites
• Others
• Global Chronic Myeloid Leukemia Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Chronic Myeloid Leukemia Treatment Market, By Region:
• North America
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • U.S.
  • Canada
• Latin America
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Teva Pharmaceutical Industries Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Takeda Pharmaceutical Company Limited
• Innovent Biologics, Inc.
• Viatris Inc. (Mylan N.V.)
• Lupin
• IL-YANG PHARM CO. LTD.
• Million Health Pharmaceuticals
• Celon Labs

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Development
• PEST Analysis
• Regulatory Scenario
• Pipeline Analysis
• New Product Launch/ Approval
• Epidemiology
• Market Trends

4. COVID - 19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Government Initiatives to Combat COVID-19

5. Global Chronic Myeloid Leukemia Treatment Market, By Drug Type, 2017-2028 (US$ Million)

• Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
• Tyrosine Kinase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Imatinib (Gleevac)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Bosutinib (Bosulif)
  • Ponatinib (Iclusig)
  • Asciminib (Scemblix)
  • Others
• Antimetabolites
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Chronic Myeloid Leukemia Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Chronic Myeloid Leukemia Treatment Market, By Region, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • U.S.
  • Canada
• Latin America
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

8. Competitive Landscape

• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Novartis AG
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Bristol-Myers Squibb Company
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Takeda Pharmaceutical Company Limited
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Innovent Biologics, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Viatris Inc. (Mylan N.V.)
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Lupin
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • IL-YANG PHARM CO. LTD.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Million Health Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Celon Labs
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About Us and Sales Contact